XML 72 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2023
Commitments and Contingencies [Abstart]  
Schedule of Milestone Payments are to be made upon Achievements of Certain Conditions The aggregate amounts of the contingent milestone payments that the Group is required to pay up to different achievements of conditions and milestones under all license agreements in effect as of December 31, 2023 are below:
   Amount 
Drug molecules: up to the conditions and milestones of    
Preclinical to IND filing  $132,564 
From entering phase 1 to before first commercial sale   17,376,410 
First commercial sale   11,882,051 
Net sales amount more than certain threshold in a year   44,769,231 
Subtotal  $74,160,256 
      
Diagnostics technology: up to the conditions and milestones of     
Before FDA approval  $208,656 
   $74,368,912